1. Home
  2. RNST vs IMCR Comparison

RNST vs IMCR Comparison

Compare RNST & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNST

Renasant Corporation

HOLD

Current Price

$37.39

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$36.16

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNST
IMCR
Founded
1904
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RNST
IMCR
Price
$37.39
$36.16
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$43.17
$67.00
AVG Volume (30 Days)
534.6K
338.1K
Earning Date
01-27-2026
11-06-2025
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
1.84
N/A
Revenue
$775,309,000.00
$379,590,000.00
Revenue This Year
$43.37
$32.31
Revenue Next Year
$13.13
$10.50
P/E Ratio
$20.23
N/A
Revenue Growth
13.04
28.11
52 Week Low
$26.97
$23.15
52 Week High
$40.40
$40.72

Technical Indicators

Market Signals
Indicator
RNST
IMCR
Relative Strength Index (RSI) 67.59 46.47
Support Level $36.82 $35.35
Resistance Level $37.43 $40.71
Average True Range (ATR) 0.71 1.91
MACD 0.21 -0.47
Stochastic Oscillator 89.45 10.07

Price Performance

Historical Comparison
RNST
IMCR

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: